The addition of a third anti-malarial drug matching the pharmacokinetic characteristics of the
slowly eliminated partner drug in artemisinin-based combination therapy (ACT) has been …

Background Artemisinin and partner-drug resistance in Plasmodium falciparum are major
threats to malaria control and elimination. Triple artemisinin-based combination therapies …

Three-day artemisinin-based combination therapy (ACT) is the current standard of care for
the treatment of malaria. However, specific drug resistance associated with reduced efficacy …

The spread of multi-drug resistance in P. falciparum limits the choice of effective antimalarial
drugs in many endemic areas. The efficacy of the major antimalarial drugs has declined in …

Malaria remains a major cause of morbidity and mortality in Africa, particularly in children
under five years of age. Availability of effective anti-malarial drug treatment is a cornerstone …

This paper examines the far-reaching implications of Triple Artemisinin-Based Combination
Therapy (TACT) in the global battle against malaria. Artemisinin-Based Combination …

Background Artemisinin-based combination therapy (ACT) was deployed in 2005 as an
alternative to chloroquine and is considered the most efficacious treatment currently …

Parasite resistance to conventional antimalarial medicines has led, in recent years, to a
dramatic shift in malaria treatment. Sixty-seven countries with endemic Plasmodium …

Unless new strategies are deployed to combat malaria, the already enormous health and
economic burden related to the disease in tropical countries is bound to worsen. The main …

Introduction Triple artemisinin-based combination therapies (TACTs) are being developed
as a response to artemisinin and partner drug resistance in the treatment of falciparum …